NMNH: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder. 2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability. 3. Exclusive “Bonpure” seven-step purification technology, high purity(up to 99%) and stability of production of NMNH powder 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder 5. Provide one-stop product solution customization service
NADH: 1. Bonzyme whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive Bonpure seven-step purification technology, purity up higher than 98 % 3. Special patented process crystal form, higher stability 4. Obtained a number of international certifications to ensure high quality 5. 8 domestic and foreign NADH patents, leading the industry 6. Provide one-stop product solution customization service
NAD: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Stable supplier of 1000+ enterprises around the world 3. Unique “Bonpure” seven-step purification technology, higher product content and higher conversion rate 4. Freeze drying technology to ensure stable product quality 5. Unique crystal technology, higher product solubility 6. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products
NMN: 1. “Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive“Bonpure”seven-step purification technology, high purity(up to 99.9%) and stability 3. Industrial leading technology: 15 domestic and international NMN patents 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products 5. Multiple in vivo studies show that Bontac NMN is safe and effective 6. Provide one-stop product solution customization service 7. NMN raw material supplier of famous David Sinclair team of Harvard University
Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.
As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.
In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.
The main methods of NMNH powder preparation include extraction, fermentation, fortification, biosynthesis and organic matter synthesis. Compared with other preparations, the whole enzyme becomes the mainstream method owing to the advantages of pollution free, high level of purity and
1. "Bonzyme" Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder.
2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability.
3. Exclusive “Bonpure” seven-step purification technology, high purity (up to 99%) and stability of production of NMNH powder
4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder
5. Provide one-stop product solution customization service
When applied to cultured cells, the NMNH is shown to be more efficient than NMN as it was able to “significantly increase NAD+ at a ten times lower concentration (5 µM) than that needed for NMN”. Moreover, NMNH shows to be more effective , as at 500 µM concentration, it achieved “an almost 10-fold increase in the NAD+ concentration, while NMN was only able to double NAD+ content in these cells, even at 1 mM concentration.”.
Interestingly, NMNH also appears to act quicker and has a longer-lasting effect compared to NMN. According to the authors, NMNH induces a “significant increase in NAD+ levels within 15 minutes”, and “NAD+ steadily increased for up to 6 hours and remained stable for 24 hours, while NMN reached its plateau after only 1 hour, most likely because the NMN recycling pathways to NAD+ had already become saturated.”.
NADH is synthesized by the body and thus is not an essential nutrient. It does require the essential nutrient nicotinamide for its synthesis, and its role in energy production is certainly an essential one. In addition to its role in the mitochondrial electron transport chain, NADH is produced in the cytosol. The mitochondrial membrane is impermeable to NADH, and this permeability barrier effectively separates the cytoplasmic from the mitochondrial NADH pools. However, cytoplasmic NADH can be used for biologic energy production. This occurs when the malate-aspartate shuttle introduces reducing equivalents from NADH in the cytosol to the electron transport chain of the mitochondria. This shuttle mainly occurs in the liver and heart.
Nicotinamide adenine dinucleotide (NAD+ ) homeostasis is constantly compromised due to degradation by NAD+ -dependent enzymes. NAD+ replenishment by supplementation with the NAD+ precursors nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) can alleviate this imbalance. However, NMN and NR are limited by their mild effect on the cellular NAD+ pool and the need of high doses. Here, we report a synthesis method of a reduced form of NMN (NMNH), and identify this molecule as a new NAD+ precursor for the first time. We show that NMNH increases NAD+ levels to a much higher extent and faster than NMN or NR, and that it is metabolized through a different, NRK and NAMPT-independent, pathway. We also demonstrate that NMNH reduces damage and accelerates repair in renal tubular epithelial cells upon hypoxia/reoxygenation injury. Finally, we find that NMNH administration in mice causes a rapid and sustained NAD+ surge in whole blood, which is accompanied by increased NAD+ levels in liver, kidney, muscle, brain, brown adipose tissue, and heart, but not in white adipose tissue. Together, our data highlight NMNH as a new NAD+ precursor with therapeutic potential for acute kidney injury, confirm the existence of a novel pathway for the recycling of reduced NAD+ precursors and establish NMNH as a member of the new family of reduced NAD+ precursors.
First, inspect the factory. After some screening, NMNH companies that directly face consumers pay more attention to brand building. Therefore, for a good brand, quality is the most important thing, and the first thing to control the quality of raw materials is to inspect the factory. Bontac company actually manufacturing NMNH powder of high quality with the caterias of SGS. Secondly, the purity is tested. Purity is one of the most important parameters of NMN powder. If high purity NMNH cannot be guaranteed, the remaining substances are likely to exceed the relevant standards. As the attached certificates demonstrates that the NMNH powder produced by Bontac reach the purity of 99%. Finally, a professional test spectrum is needed to prove it. Common methods for determining the structure of an organic compound include Nuclear Magnetic Resonance Spectroscopy (NMR) and high-resolution mass spectrometry (HRMS). Usually through the analysis of these two spectra, the structure of the compound can be preliminarily determined.
1. Introduction On January 9, 2024, the expert team of selection organizing committee from Deloitte visited BONTAC, and presented the trophy of “China Life Sciences & Healthcare Rising Star” to BONTAC on site. By virtue of its unique and innovative technology in the field of coenzymes, professional R&D team with rich experience, and excellent performance in the industry of biosynthesis, BONTAC has stood out from the crowd and won the award of "Deloitte China Life Sciences & Healthcare Rising Star". 2. 2023 Deloitte China Life Sciences & Healthcare Rising Star Since the launch of “Deloitte China Life Sciences & Healthcare Rising Star” campaign by the end of June 2023, extensive attention has been attracted by the Chinese medicine and health industry. Following verification by site visit of the enterprises, 50 enterprises with prominent comprehensive strength are finally determined to be eligible, which are subjected to rigorous review of multiple dimensions such as financial asset valuation, founding team, technical innovation, market prospect, industrial rank, etc. The awarded enterprises in this selection campaign encompass the advanced enterprise in the niche areas of life sciences and healthcare, who comprehensively display their multiple innovation achievements in the field of life sciences and healthcare. The “Deloitte China Life Sciences & Healthcare Rising Star” selection campaign is a key subproject of Deloitt on the selection project of high-tech and fast-growing enterprises, aiming to recognize and award the outstanding enterprises who take the lead in their niche areas of life sciences and healthcare and have great growth potential. 3. The candidate enterprises must meet the the following criteria: * Business headquartered within China Mainland, Hong Kong or Macao. * Own leading technology and viable business models. * Have extensive growth potential with a leading position in their niche segments. 4. Current situation on Chinese medicine and health industry The technical innovation and product quality in Chinese medicine and health industry have continuously improved, which is driven by healthcare reform policies, emerging technologies and capital markets. In China, independent innovation has penetrated into all tracks of the major health industry, which greatly promotes the research and development of domestically produced innovative medicines and medical technologies. Substantial promising innovative enterprises has emerged and gradually gained recognition in the global market, ranking among the first echelon of global technological innovation. 5. About BONTAC BONTAC is the pioneer of NMN industry and the first manufacturer to launch NMN mass production, with the first whole-enzyme catalysis technology around the world. At present, BONTAC has become the leading enterprise in niche areas of coenzyme products. Notably, BONTAC is the NMN raw material supplier of famous David Sinclair team at the Harvard University, who uses the raw materials of BONTAC in a paper titled “Impairment of an Endothelial NAD+-H2S Signaling Network Is a Reversible Cause of Vascular Aging”. Our services and products have been highly recognized by global partners. Furthermore, BONTAC has the first national and the only provincial independent coenzyme engineering technology research center in Guangdong, China. The coenzyme products of BONTAC are widely used in fields such as nutritional health, biomedicine, medical beauty, daily chemicals and green agriculture. BONTAC adheres to independent innovation, with more than 160 invention patents. In the future, BONTAC will adhere to the innovation-driven concept, continue to increase investment in research and development, dig into the field of synthetic biology, and commit to developing more high-quality raw material products. At the same time, BONTAC will actively expand the international market, and work with global partners to promote the prosperous development of synthetic biology industry. In this era full of challenges and opportunities, BONTAC is confident to make greater contributions to the cause of human health.
Introduction According to the report of International Agency for Research on Cancer (IARC), there are 19.3 million new cases of malignant tumors and 10 million deaths worldwide in 2020. Malignant tumors have overtaken cardiovascular disease as the leading cause of human death. By dirt of low toxicity and potential pharmacological properties including anticancer effects, ginseng has gained much attention. The compounds derived from ginseng can sensitize cancer cells to anticancer therapy. One of the potential merits of ginseng-derived compounds lies in their targeting ability to cancer stem cells (CSCs). About CSCs CSCs are a specific subset of cells that possess high capabilities of self-renewal, differentiation potential, tumorigenicity and drug resistance. They are resistant to non-specific treatment methods such as chemotherapy and radiotherapy, and play a crucial role in tumor initiation, metastasis, drug resistance, and recurrence. CSCs can generate multiple types of tumor cells and are intimately engaged in the entire process of cancer development and progression. Specifically, CSCs can interact with tumor surveillance microenvironment components to support the expansion of the tumor as the primary tumor growth mechanism. Besides, cells with stemness properties transition to invasiveness, persist, and translocate to metastatic sites while remaining quiescent. During colonization, CSCs can support the growth of metastatic tumors by evading immune surveillance and promoting the proliferation of quiescent CSCs. About ginseng-derived compounds Physiologically active compounds derived from ginseng can be categorized into ginseng saponin (e.g., ginsenosides) and non-saponin compounds (e.g., polysaccharides, peptides, polyacetylenes, phenolic compounds, terpenes, and fatty acids). Among them, ginsenosides are the most extensively researched bioactive compounds due to their distinctive presence in Panax ginseng. They can be further categorized according to the structure of their genin (aglycon): the four-ring dammarane family and the oleanane family, with protopanaxadiols (e.g., Rb1, Rb2, Rg3, Rh2 and Rh3) and protopanaxatriols (e.g., Rg1, Rg2, and Rh1) being the main functional categories within the dammarane family. CSC-targeting activity of ginseng-derived compounds with known mechanisms Ginseng-derived compounds can modulate CSC-related signaling pathways and reduce the CSC population. Currently, the known signaling pathways of ginseng-derived compounds, such as Wnt/β-catenin, Notch, Hh, NF-κB, JAK-STAT, and PI3K/Akt pathways, have been proven to participate in regulation of CSCs. For instance, in ginseng saponin compounds, Rg3 can inhibit the Wnt/β-catenin pathway to hamper the viability and self-renewal of patient-derived GBM stem cells. Rh2 can repress CSC in skin squamous cell carcinoma through affecting the crosstalk between autophagy and β-catenin pathway. In non-saponin compounds, panaxynol can hinder the progression of lung cancer via inhibition of Hsp90, a novel cellular target for the development of anti-CSC agents. Conclusion Ginseng-derived compounds that target cancer stem cells hold significant promise for treating a broad spectrum of cancers. Further research is essential to fully understand the intricate molecular mechanisms underlying the pharmacological activities of these compounds. This deeper understanding may pave the way for the development of more potent and targeted anti-cancer strategies, offering new hope in the ongoing battle against cancer. Reference [1] Lee JS, Lee HY. Ginseng-derived compounds as potential anticancer agents targeting cancer stem cells [J]. J Ginseng Res. 2024;48(3):266-275. doi:10.1016/j.jgr.2024.03.003 [2] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. [3] Zhang WJ, Zhao KX, Zhang KY, et al. Advances in the biological characteristics and stem maintenance mechanisms of tumor stem cells[J]. Chin J Biotech, 2024, 40(2): 391-418. BONTAC Ginsenosides BONTAC has been dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, with self-owned factories, over 180 global patents as well as strong R&D team. BONTAC has rich R&D experience and advanced technology in the biosynthesis of rare ginsenosides Rh2/Rg3, with pure raw materials, higher conversion rate and higher content (up to 99%). One-stop service for customized product solution is available in BONTAC. With unique Bonzyme enzymatic synthesis technology, both S-type and R-type isomers can be accurately synthesized here, with stronger activity and precise targeting action. Our products are subjected to strict third-party self-inspection, which are worth of trustworthy. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be responsible for any claims, damages, losses, expenses, or costs arising directly or indirectly from your reliance on the information and material on this website.
As a leading player in the world of biotechnology, BONTAC is at the forefront of driving innovation and transforming the industry. Our unwavering commitment to scientific excellence and our deep understanding of the complex interplay between biology and technology have enabled us to develop a suite of cutting-edge biotechnology products that are poised to redefine the landscape. NADH: a typical Biotechnology Product At the heart of our biotechnology product portfolio is our focus on NADH, a remarkable coenzyme that plays a pivotal role in cellular processes. NADH, a reduced form of β-nicotinamide adenine dinucleotide, is a crucial component in substance and energy metabolism, serving as a carrier and electron donor in the process of oxidative phosphorylation. This mitochondrial hormone is essential for maintaining cell growth, differentiation, and energy metabolism, as well as providing cytoprotection. Unlocking the Potential of Biotechnology with NADH With the power of BONTAC biotechnology, the effectiveness of NADH has been fully exploited and has been widely used in several fields. From biopharmaceuticals and nutraceuticals to cosmeceuticals and beyond, our NADH-based solutions are designed to address the evolving needs of the biotechnology industry, empowering our partners to push the boundaries of what's possible. Boosting Cellular Metabolism and Energy Production One of the key advantages of our biotechnology products is their ability to enhance cellular metabolism and energy production. By providing a readily available source of NADH, our solutions help to optimize the function of mitochondria, the powerhouses of the cells. This, in turn, leads to improved energy generation, better cellular resilience, and enhanced overall cellular health, all of which are crucial for driving advancements in the biotechnology field. Promoting Cellular Rejuvenation and Longevity Alongside our focus on cellular metabolism, BONTAC's biotechnology products also address the critical issue of cellular aging and senescence. By supporting the body's natural ability to clear senescent cells and promote the regeneration of healthy, youthful cells, our NADH-based solutions can help reverse the signs of cellular aging and unlock the remarkable potential of cellular rejuvenation. Versatility and Customization The versatility of our biotechnology products is a testament to our innovative approach. We work closely with our partners to tailor our NADH-based solutions to their specific needs, ensuring that they have access to the most effective and cutting-edge biotechnology tools available. Whether it's developing novel biopharmaceuticals, enhancing nutraceutical formulations, or extending cosmeceutical applications, BONTAC's biotechnology products can deliver significant results. Conclusion As the biotechnology landscape continues to evolve, BONTAC remains committed to pushing the potential boundaries. Our innovative biotechnology products, powered by the remarkable capabilities of NADH, are poised to revolutionize the industry, empowering our partners to unlock new frontiers in cellular health, energy production, and rejuvenation. By embracing our unwavering dedication to scientific excellence and our relentless pursuit of innovation, we are confident that BONTAC will continue to shape the future of biotechnology, one breakthrough at a time.